Summary From 1979From -1983 
In the 1970's it was established that cyclical combination chemotherapy (MOPP or MVPP) was effective treatment for advanced Hodgkin's disease (De Vita et al., 1970; Nicholson et al., 1970) . Remission rates of above 75% have been obtained with MOPP and over half of such patients have remained in long-term remission (Longo et al., 1986) . However, MOPP and MVPP proved toxic, particularly with regard to the mustine, which caused considerable nausea and vomiting and a high incidence of local tissue reactions (particularly phlebitis). The substitution of chlorambucil (Leukeran) appeared to give equally favourable results with less toxicity (McElwain et al., 1977) . Long term follow-up of the Royal Marsden Hospital data reported in this Journal confirms this early conclusion (Selby et al., 1990) . Between 1979 and 1983 the British National Lymphoma Investigation (BNLI) conducted a randomised multicentre study of MOPP against LOPP (Leukeran substituted for mustine) and reported that LOPP appeared to be as effective as MOPP and less toxic (Hancock, 1986) . Long-term results of this study are reported here.
Methods

Patient selection
The criteria for inclusion were as follows:
(1) Opportunity for adequate long-term follow-up must have been anticipated. (Bennett et al., 1985) . The patient characteristics of the groups analysed for survival are shown in Table I Multivariate analyses were made using the Cox model (Cox, 1972) . Survival curves were calculated by the life table method and statistical comparison of curves carried out by the log rank test as described by Peto et al. (1977) and by the Mantel test (1966) .
The deaths of patients who remained in complete remission from their first course of treatment until their time of death who died from causes other than HD were censored in the disease-free and relapse-free curves, but were included in the curve for overall survival.
Results
The percentage of patients who achieved complete remission (CR) from initial MOPP was 63%, and from initial LOPP was 57%: the percentage of these patients remaining relapsefree at 5 years was 61% for both MOPP and LOPP ( Figure  1 ). Freedom from HD at 5 years was 38% for MOPP and 35% for LOPP (Figure 2 ). The overall survival (OS) at 5 Acute toxicity Acute toxicity data were given in the initial BNLI report (Hancock, 1986 (Table III) . Death in both groups was mostly related to disseminated HD, often with terminal infection, but in the MOPP arm five patients died from second malignancies, and in the LOPP arm three: six of these eight patients were in CR from their HD at time of death. A further eight deaths occurred in CR: one in the LOPP arm (myocardial infarct), and seven in the MOPP arm (two myocardial infarcts, one idiopathic thrombocytopenic purpura, one pneumonia, one congestive heart failure, one motor neurone disease, one road traffic accident).
Discussion
The complete remission rates reported here with MOPP and LOPP chemotherapy in Stage III/IV Hodgkin's disease (71% clinically staged) are almost identical, as are the percentages of patients remaining disease free and the overall survival up to 10 years.
The results obtained with MOPP are in line with the previous BNLI experience. In 532 patients who received initial MOPP chemotherapy the CR rate was 61% with an overall survival at 10 years of 52%. In the 369 patients with Stage IIIB/IV disease, the CR rate was 59% with an overall survival at 5 and 10 years of 62% and 47% respectively.
The CR rates reported here with MOPP and LOPP are less than those reported in the initial MOPP study from the NCI (Longo et al., 1986) and the ChlVPP study reported from the Royal Marsden Hospital (Selby et al., 1990) . In the latter series of 284 patients with Stages I and IT (poor prognosis) and III and IV Hodgkin's disease, 85% of the 229 previously and 65% at 5 and 10 years respectively. Several possibilities exist for the apparent differences between these reports. Firstly the patient selection may differ. Only 29% of the patients reported in the BNLI study were pathologically staged compared to 45% in the Marsden series. All the patients in the BNLI study were Stage III or IV, but the same is true of the NCI cohort and, if one looks only at the clinically staged III and IV patients in the Marsden series the CR rate is still higher at 79%. The dosages of chlorambucil and of procarbazine in the BNLI LOPP regime were less than that in the Marsden ChlVPP regime and this may have accounted for the lower response rate. Alternatively there may be significant differences between series in the criteria for definition of CR.
If one by contrast looks at overall survival then there is remarkable conformity of results. In the NCI MOPP study the 10 year survival was 52% which is identical to the BNLI experience. The LOPP data in this paper shows a 5 year overall survival of 64% and an approximate value of 55% at 10 years, which is similar to the 62% at 10 years for Stage III/IV patients reported in the Marsden series for ChlVPP. For Stage IV patients the overall survival at 5 years was 65% in both series.
Implicit in the fact that a lower CR has been reported with a similar overall survival is that successful salvage therapy has been possible. In this context it is worth noting that 57 of the 290 patients relapsed or had residual disease in nodal areas and were treated with radical radiotherapy. Of these, 37 are alive and 24 remain disease free following radiotherapy. It is also possible that patients treated less intensively with first line chemotherapy are more amenable to salvage with second line chemotherapy.
Multivariate analysis confirms the importance of prognostic factors in influencing survival data; for example, in our study overall survival was significantly worse for older age, unfavourable histology, 'B' symptoms and low albumin. These findings are broadly consistent with those reported for other chemotherapy regimens (reviewed by Selby et al., 1987) .
Substitution of chlorambucil for mustine in 'standard' quadruple chemotherapy represents a considerable advance in terms of improving patients' quality of life. However a large proportion of patients fail with such therapies alone and there is clearly a need for developing new strategies. Alternating or hybrid regimens, or using high dose chemotherapy (with or without autologous bone marrow transplant) may improve the outlook and the BNLI is currently evaluating such approaches in randomised studies.
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